Study of chemo plus lorlatinib for ALK+ lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 4 ALK-positive non-small cell lung cancer.
- Your cancer has gotten worse in areas outside the brain while you were taking lorlatinib.
- You are at least 18 years old.
- You are in good enough health to be active and out of bed (ECOG 0 or 1).
- You have tumors that can be measured on scans, and cancer in the brain is either absent or stable.
- Your kidney, bone marrow, and liver function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to manage high cholesterol (hyperlipidemia) that happens as a side effect of the drug lorlatinib, which is used to treat ALK-positive lung cancer. Participants will receive additional cholesterol-lowering medicines or strategies, and the study aims to find the best way to keep cholesterol in check while continuing effective cancer treatment.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial compares a newer targeted pill (lorlatinib) with standard chemoradiation (chemo plus radiation) for people with stage III ALK-positive lung adenocarcinoma. The goal is to see if lorlatinib alone works better than standard treatment and causes fewer side effects.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.